LTF and hepatocellular carcinoma: In a study, Abdelmoneem et al. were inspired by the targeting action of lactoferrin (LF) via binding to LF receptors overexpressed by HCC cells, and lactoferrin shell-coated oily core nanocapsules (LF-NCs), glycyrrhetinic acid (GA)-targeted and lactobionic acid (LA)-targeted LF-NCs were fabricated for the combined delivery of hydrophobic drugs, sorafenib (SFB) and quercetin (QRC), and they proposed a potential therapeutic HCC strategy.